Skip to main content
SpringerLink
Log in

Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience

  • Conference paper
Immunotherapy of Renal Cell Carcinoma

Abstract

Interleukin-2 (IL-2) and interferon alpha (IFNα) are immunomodulatory cytokines which can now be produced in bulk using recombinant DNA techniques. The availability of these agents has rejuvenated the field of cancer immunotherapy, and clinical trials utilizing them have been performed with a variety of malignancies. Because renal cell carcinoma (RCC) is resistant to traditional systemic therapies and because earlier immunotherapy trials had suggested that it may be susceptible to immunologic therapy, this tumor system has been among the most intensively studied in trials investigating the therapeutic potential of these new biological agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goldstein D, Laszlo J (1986) Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315–4329

    PubMed  CAS  Google Scholar 

  2. Lindahl P, Leary P, Gresser I (1972) Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69: 721–725

    Article  PubMed  CAS  Google Scholar 

  3. Murray JL, Rosenblum MG et al. (1986) Differential in vitro effects of alpha recombinant interferon and gamma recombinant interferon on the expression of melanoma eassociated antigens (MAA) P97 and 240 Kd on melanoma cell line Ts294. Proc Natl Acad Sci USA 27: 313

    Google Scholar 

  4. Giacomini P, Aguzzi A, Pestka S et al. (1984) Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA and tumor-associated antigens by human melanoma cells. J Immunol 133: 1649–1655

    PubMed  CAS  Google Scholar 

  5. Rosenblum MG, Lamki LM, Murray JL etal. (1988) Interferon-induced changes in pharmacokinetics and tumor uptake of 111 In-labelled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80: 160–165

    Article  PubMed  CAS  Google Scholar 

  6. Herberman RB, Ortaldo JR, Mantovani A etal. (1982) Effect of human recombinant interferon on cytotoxic activity of natural killer ( NK) cells and monocytes. Cell Immunol 67: 160–167

    Article  PubMed  CAS  Google Scholar 

  7. Brunda RB, Rosenbaum D (1934) Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 44: 597–601

    Google Scholar 

  8. Brunda MJ, Rosenbaum D, Stern L (1984) Inhibition of experimentally-induced metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastses. Int J Cancer 24: 421–426

    Article  Google Scholar 

  9. Suzuki R, Suzuki S, Ebina N, Kumagai K (1985) Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2. J Immunol 134: 2139–2148

    PubMed  CAS  Google Scholar 

  10. Herberman RB (1980) Natural cell mediated immunity against tumors. Academic Press, New York

    Google Scholar 

  11. Henney CS, Huribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural keller cell activity. Nature 291: 335–338

    Article  PubMed  CAS  Google Scholar 

  12. Stotter H, Rude E, Wagner H (1980) T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol 10: 719–722

    Article  PubMed  CAS  Google Scholar 

  13. Errard F, Corthesy P, Nabhol M etal. (1985) Interleukin-2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Immunol 134: 1644–1651

    Google Scholar 

  14. Fisher RI, Coltman CA, Doroshow JH etal. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108: 518–523

    PubMed  CAS  Google Scholar 

  15. Bukowski RM, Goodman P, Crawford ED et al. (1989) Phase II evaluation of recombinant interleukin-2 (rIL-2) in metastatic renal cell carcinoma (RCC): SWOG 8617. Proc ASCO 8: 143

    Google Scholar 

  16. Branda MJ, Tarnowski D, Davatelis V (1986) Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int J Cancer 37: 797–793

    Google Scholar 

  17. Chikkala NF, Lewis I, Ulchaker, Finke JH et al. (1990) Interactive effects of a- interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res 50: 1176–1182

    PubMed  CAS  Google Scholar 

  18. Bgo M, Sakurai M, Tamura T et al. (1988) In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 48: 260–264

    Google Scholar 

  19. Budd GT, Osgood B, Barna B et al. (1989) Phase I clinical trial of interleukin 2 and a-interferon: toxicity and immunologic effects. Cancer Res 49: 6432–6436

    PubMed  CAS  Google Scholar 

  20. Budd GT, Sergi J, Barna B etal. (1989) Phase I trial of interleukin-2 (RIL-2) and INFa (rHuIFNa2a) in human malignancy. Proc Natl Acad Sci USA 30: 362

    Google Scholar 

  21. McKeever S, Funke J, Murthy S et al. (1989) Phase la/lb trial of high dose continuous infusion (CI) interleukin-2 (rJL-2) and interferon (rHuIFNa2a): preliminary clinical and laboratory results. Proc Am Assoc Cancer Res 30: 238

    Google Scholar 

  22. Lee KH, Talpaz M, Rohberg JM et al. (1989) Concimitant administration of recom¬binant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol 7: 1726–1732

    PubMed  CAS  Google Scholar 

  23. Edwards BS, Hawkins MJ, Borden EC (1984) Comparative in vivo and in vitro acti¬vation of human natural killer cells by recombinant a-interferons differing in antiviral activity. Cancer Res 44: 3135–3139

    PubMed  CAS  Google Scholar 

  24. Edwards BS, Merritt JA; Fuhlbrigge RC, Borden EC (1985) Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 75: 1908–1913

    Article  PubMed  CAS  Google Scholar 

  25. Phillips JH, Gemlo BT, Myers WW et al. (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 5: 1933–1941

    PubMed  CAS  Google Scholar 

  26. Tubbs R, Budd GT, Finke J et al. (1990) Cellular infiltrates in tumor specimens from patients treated with cytokines and adoptive cellular therapy. Proc Am Assoc Cancer Res 31: 175

    Google Scholar 

  27. Rubin JT, Elwood U, Rosenberg SA, Lotze MT (1989) Immunohistochemical corre¬lates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 49: 7086 - 7092

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. One Clinic Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    R. M. Bukowski

Authors
  1. G. T. Budd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Sergi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Barna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Boyett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Medendorp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Tubbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V. Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. E. Pontes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, University Hospital Nijmegen, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Frans M. J. Debruyne MD, Ph.D. (Director Chairman) (Director Chairman)

  2. Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44106, Cleveland, Ohio, USA

    Ronald M. Bukowski MD (Director, Clinical Research) (Director, Clinical Research)

  3. Department of Urology, Wayne State University, 4160 John R., Suite 1017, 48201, Detroit, Michigan, USA

    J. Edson Pontes MD, Ph.D. (Professor and Chairman) (Professor and Chairman)

  4. Department of Medical Oncology, University Hospital Nijmegen, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Pieter H. M. de Mulder MD, Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Budd, G.T. et al. (1991). Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience. In: Debruyne, F.M.J., Bukowski, R.M., Pontes, J.E., de Mulder, P.H.M. (eds) Immunotherapy of Renal Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75853-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75853-9_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52835-7

  • Online ISBN: 978-3-642-75853-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation